A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation
Latest Information Update: 21 May 2024
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 28 Sep 2023 Status changed from active, no longer recruiting to completed.
- 12 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Sep 2023.